Thus, inhibition of Wnt/β-catenin signaling by novel anticancer agents might have a therapeutic impact on suppression of PDACs driven by this pathway in Gal-4 high expressing pancreatic tumors. This evidence concerns the gene LGALS4 and pancreatic neoplasm.